Compare Eli Lilly And Co (LLY) vs Global X NASDAQ 100 Covered Call ETF (QYLD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eli Lilly And Co vs Global X NASDAQ 100 Covered Call ETF — how do they compare? Eli Lilly And Co trades at $1,221.01 (market cap $1.08T), while Global X NASDAQ 100 Covered Call ETF trades at $18.16. The key difference: Eli Lilly And Co pays a 0.57% dividend while Global X NASDAQ 100 Covered Call ETF pays none. Which is the better fit depends on your goals.
| LLY | QYLD | |
|---|---|---|
Market Cap | $1.08T | — |
Sector | Health | Income / Options Overlay |
52-Week High | $1.24K | $18.52 |
52-Week Low | $639.43 | $16.46 |
Enterprise Value | $1.13T | — |
Dividend Yield | 0.57% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eli Lilly (LLY) trades at $1,223.97, down 0.62% on the day, maintaining strong bullish momentum with consecutive earnings beats and robust revenue growth. The stock shows technical strength above key support levels at $1,207, while fundamentals reveal exceptional profitability with 33.53% net margins and 102.44% ROE. Recent quarterly results exceeded expectations, with Q2 2026 revenue surging 48% to $23 billion driven by Mounjaro and Zepbound demand.
Outlook remains positive with analyst consensus targeting $1,380 and 73% buy ratings, though elevated valuations (P/E 40.8) and regulatory risks around weight-loss drug competition present headwinds. The company's pipeline advancement with retatrutide filing expected in 2027 provides medium-term growth catalysts, but investors should monitor execution risks in the competitive obesity drug market.
QYLD trades at $18.18, up 0.17% with a bullish technical signal from moving averages but bearish oscillators. The ETF maintains its covered call strategy, generating consistent monthly dividends, though financial ratios are unavailable. Recent news highlights both the appeal of its 11.67% yield and concerns about long-term underperformance versus the Nasdaq-100.
Outlook: High income potential in sideways markets, but capital appreciation is limited. Risks include erosion of NAV during bull markets and competition from lower-fee alternatives. Suitable for income-focused investors willing to sacrifice growth for yield.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →About Global X NASDAQ 100 Covered Call ETF
QYLD is an ETF that follows a covered call strategy on the NASDAQ 100 Index. The fund holds a long position in the stocks of the NASDAQ 100 and simultaneously writes (sells) call options on the index. The primary goal is to generate monthly income from the option premiums. This strategy can reduce portfolio volatility and provide income, but it limits potential capital appreciation from a significant rise in the NASDAQ 100 Index.
Read more on QYLD →
